Jane Street Group LLC grew its stake in Mesoblast Limited (NASDAQ:MESO - Free Report) by 46.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,102 shares of the company's stock after purchasing an additional 26,959 shares during the period. Jane Street Group LLC owned about 0.07% of Mesoblast worth $695,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in MESO. Marshall Wace LLP bought a new position in Mesoblast in the second quarter worth $562,000. XY Capital Ltd acquired a new position in shares of Mesoblast in the 3rd quarter valued at $244,000. Creative Planning bought a new position in shares of Mesoblast during the 3rd quarter worth about $147,000. XTX Topco Ltd acquired a new stake in shares of Mesoblast during the 2nd quarter valued at about $103,000. Finally, Rathbones Group PLC bought a new stake in Mesoblast in the second quarter valued at about $95,000. Institutional investors own 1.43% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on MESO. Jefferies Financial Group cut shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Monday, December 23rd. Maxim Group upgraded Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price for the company in a research report on Tuesday, September 24th. Finally, Piper Sandler upped their price target on Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a research report on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Mesoblast has an average rating of "Hold" and a consensus price target of $13.50.
Read Our Latest Stock Analysis on MESO
Mesoblast Trading Down 2.4 %
Shares of NASDAQ MESO traded down $0.49 during mid-day trading on Friday, hitting $20.12. 295,548 shares of the stock were exchanged, compared to its average volume of 454,524. Mesoblast Limited has a twelve month low of $1.61 and a twelve month high of $22.00. The stock's fifty day simple moving average is $12.36 and its two-hundred day simple moving average is $9.10. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.
About Mesoblast
(
Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Read More
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
